Industry News

Pharmaceutical Industry News

Glaukos is teaming up with…

September 24th, 2026|Fierce Pharma|

Glaukos is teaming up with four-time NBA champion, two-time NBA Most Valuable Player and Olympic gold medalist Stephen Curry for a new “Could it be KC?” campaign.

Otsuka ICU Medical, a joint…

September 24th, 2026|Fierce Pharma|

Otsuka ICU Medical, a joint venture from Japan’s Otsuka Pharmaceutical Factory, issued a voluntary recall of one lot of 0.9% sodium chloride injection for IV due to a possible mix-up of labels.

Biogen has teamed with gymnast…

September 24th, 2026|Fierce Pharma|

Biogen has teamed with gymnast Suni Lee for a campaign, leveraging the Olympic gold medalist’s health journey and social media audience to vault deeper into kidney health awareness.

Sign-ups for Medicare’s GLP-1…

September 23rd, 2026|Fierce Pharma|

Sign-ups for Medicare’s GLP-1 coverage plan keep expanding, and Eli Lilly is dominating the market with 70% share, the company’s CEO David Ricks said.

Despite hitting a speed bump over…

September 23rd, 2026|Fierce Pharma|

Despite hitting a speed bump over the summer, automated cell therapy manufacturing specialist Cellares has continued to sign new partners at a steady pace, now inking a second agreement with an Asia-based organization in just

AstraZeneca has re-upped its…

September 23rd, 2026|Fierce Pharma|

AstraZeneca has re-upped its UNICEF-partnered Young Health Programme, committing to a new five-year phase that will move total investment in the initiative above $100 million.

Genentech’s chief marketing…

September 22nd, 2026|Fierce Pharma|

Genentech's chief marketing officer Zoë Lazarre, Ph.D., likens AI to a “armor, or a digital backpack” that her teams can use for better, faster insights, she said during an interview at Fierce Pharma Week.

Bristol Myers Squibb plans to lay…

September 22nd, 2026|Fierce Pharma|

Bristol Myers Squibb plans to lay off another 265 employees tied to its corporate headquarters in New Jersey, bringing the number of total job reductions the company has announced this year in the Garden State

As China and the U.S. presently…

September 22nd, 2026|Fierce Pharma|

As China and the U.S. presently duke it out over biopharma innovation supremacy, a clutch of Europe’s biggest drugmakers are calling on the bloc to not lose sight of its R&D roots.

Eric Dube, Ph.D., the CEO who…

September 22nd, 2026|Fierce Pharma|

Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will step down to “focus on his health and family.” Bradley Campbell, formerly CEO of

Par Health issued a voluntary…

September 22nd, 2026|Fierce Pharma|

Par Health issued a voluntary recall of two lots of the IV sedative dexmedetomidine HCl in 0.9% sodium chloride injection that may be contaminated with cellulose or stopper material.

The president announced plans to…

September 21st, 2026|Fierce Pharma|

The president announced plans to split some childhood immunizations in the U.S. into five separate shots, given as “20% doses” every six months. The decision has garnered significant backlash from the medical community.

As Johnson & Johnson’s $14.6…

September 21st, 2026|Fierce Pharma|

As Johnson & Johnson’s $14.6 billion bet on Intra-Cellular Therapies continues to pay off with blockbuster sales of Caplyta, the atypical antipsychotic has passed a phase 3 test that puts it one step closer to

Amid lawmaker and advocacy group…

September 21st, 2026|Fierce Pharma|

Amid lawmaker and advocacy group efforts to parse the White House’s “most favored nation” drug pricing deals with drugmakers, newly revealed—yet heavily redacted—information is reigniting concerns about just who exactly the Trump administration policy benefits.

IntraBio’s streak of success in…

September 21st, 2026|Fierce Pharma|

IntraBio's streak of success in the rare neurological category continues, as the drugmaker racks up a second indication for Aqneursa, now the first treatment in the world indicated for a rare ataxia.